25-Second COVID-19 Saliva Test Delivers Real-Time Results with 98% Sensitivity and 100% Specificity
|
By LabMedica International staff writers Posted on 16 Mar 2021 |

Image: Pelican COVID-19 Ultra-Rapid Mobile Test (Photo courtesy of Canary Global Inc.)
A non-invasive ultra-rapid COVID-19 saliva test delivers 98% sensitivity and 100% specificity in symptomatic and asymptomatic individuals with SARS-CoV-2, including variants, making it ideal for point-of-care (POC) diagnosis and rapid mass-screening.
Pelican Diagnostics, a Canary Global Inc. (Burlington, ON, Canada) company, has received CE Mark for a 25-second COVID-19 saliva test, delivering real-time results with 98% sensitivity and 100% specificity. The Pelican COVID-19 Ultra-Rapid Mobile Test for the detection of SARS-CoV-2 is now cleared for sale and distribution in the European Union (EU). The test is also under review at the US Food and Drug Administration (FDA) under Emergency Use Authorization (EUA) for Over-the-Counter (OTC), non-prescription use and as a self-test.
The testing kit consists of a handheld reusable digital reader and disposable testing cartridges with direct detection technology to analyze multiple targets – spike (S) and nucleocapsid (N) proteins in saliva - to detect SARS-CoV-2. With a limit of detection of 1fg /ml, it correlates well with RT-PCR reference assay, the current gold standard. Taking less than two minutes for the entire testing process, the digital antigen saliva test has high sensitivity in both symptomatic and asymptomatic users, including detection of the known new variants. The POC test detects the virus without the need for lab equipment or amplification processes. Using cutting-edge nano-sensing technology in viral detection in saliva, the Pelican test has overhauled the need for invasive nasal sampling, previously thought to be the best way to detect the virus.
The device can also be wirelessly connected to a smartphone-based app for automated reporting. A result of "positive" or "negative" is given on the screen of the reader with more information for the patient on the connected mobile app. Each disposable test cartridge contains multiple sensors and a unique QR code which is linked to the user's cell phone or another connected device. The cloud-based testing system is HIPAA compliant which protects the integrity of protected health information of users.
"Combining the power of nanosensor and digital detection technology, the Pelican CV19 test is the first point of care test that can return an accurate result with a 98% sensitivity and 100% specificity in less than 2 minutes," said Raj Reddy, President and CEO of Canary Global Inc. "The challenge with current rapid tests is that too often results are delivered after transmission already has begun. The more sensitive PCR tests take too long and are not suitable as point of care tests. Together with vaccine rollout, rapid, accurate and frequent testing on a connected platform to improve contact tracing is what is needed to stop the pandemic. This is what Pelican can provide."
Related Links:
Canary Global Inc.
Pelican Diagnostics, a Canary Global Inc. (Burlington, ON, Canada) company, has received CE Mark for a 25-second COVID-19 saliva test, delivering real-time results with 98% sensitivity and 100% specificity. The Pelican COVID-19 Ultra-Rapid Mobile Test for the detection of SARS-CoV-2 is now cleared for sale and distribution in the European Union (EU). The test is also under review at the US Food and Drug Administration (FDA) under Emergency Use Authorization (EUA) for Over-the-Counter (OTC), non-prescription use and as a self-test.
The testing kit consists of a handheld reusable digital reader and disposable testing cartridges with direct detection technology to analyze multiple targets – spike (S) and nucleocapsid (N) proteins in saliva - to detect SARS-CoV-2. With a limit of detection of 1fg /ml, it correlates well with RT-PCR reference assay, the current gold standard. Taking less than two minutes for the entire testing process, the digital antigen saliva test has high sensitivity in both symptomatic and asymptomatic users, including detection of the known new variants. The POC test detects the virus without the need for lab equipment or amplification processes. Using cutting-edge nano-sensing technology in viral detection in saliva, the Pelican test has overhauled the need for invasive nasal sampling, previously thought to be the best way to detect the virus.
The device can also be wirelessly connected to a smartphone-based app for automated reporting. A result of "positive" or "negative" is given on the screen of the reader with more information for the patient on the connected mobile app. Each disposable test cartridge contains multiple sensors and a unique QR code which is linked to the user's cell phone or another connected device. The cloud-based testing system is HIPAA compliant which protects the integrity of protected health information of users.
"Combining the power of nanosensor and digital detection technology, the Pelican CV19 test is the first point of care test that can return an accurate result with a 98% sensitivity and 100% specificity in less than 2 minutes," said Raj Reddy, President and CEO of Canary Global Inc. "The challenge with current rapid tests is that too often results are delivered after transmission already has begun. The more sensitive PCR tests take too long and are not suitable as point of care tests. Together with vaccine rollout, rapid, accurate and frequent testing on a connected platform to improve contact tracing is what is needed to stop the pandemic. This is what Pelican can provide."
Related Links:
Canary Global Inc.
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants
Channels
Clinical Chemistry
view channel
Study Questions Uniform Stool-Test Cutoff Across Age Groups
Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read more
Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine
Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more
Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreMolecular Diagnostics
view channelGenome Sequencing Provides Clues to Unexplained Recurrent Miscarriages
Recurrent pregnancy loss, defined as two or more miscarriages, affects about 5% of couples. In many cases, routine evaluation does not identify a cause, particularly when pregnancies have a normal chromosome... Read more
Genetic Test Improves Risk Prediction for Open-Angle Glaucoma
Glaucoma damages the optic nerve and is the leading cause of irreversible blindness worldwide. Because the disease often causes no early symptoms, about half of affected individuals remain undiagnosed... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
WHO Survey Reveals Gaps in Antimicrobial Resistance Testing and Response
Antimicrobial resistance (AMR) remains a major challenge for health systems, limiting effective treatment options for drug-resistant infections. These infections caused more than 1 million deaths and contributed... Read more
Direct-From-Specimen Pneumonia Test Detects Pathogens and Resistance in Hours
Pneumonia is a leading cause of sepsis and is associated with high mortality. Conventional culture-based pathogen identification and antimicrobial susceptibility testing can take two to four days, delaying... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil
Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more








